Lymphoproliferative disorders arising under immunosuppression with FK 506: initial observations in a large transplant population.
作者信息
Nalesnik M A, Demetris A J, Fung J J, Starzl T E
机构信息
Department of Surgery, University of Pittsburgh, Pennsylvania.
出版信息
Transplant Proc. 1991 Feb;23(1 Pt 2):1108-10.
Abstract
摘要
相似文献
1
Lymphoproliferative disorders arising under immunosuppression with FK 506: initial observations in a large transplant population.在使用FK 506免疫抑制情况下出现的淋巴增生性疾病：对一大群移植受者的初步观察
Transplant Proc. 1991 Feb;23(1 Pt 2):1108-10.
2
Primary central nervous system post-transplantation lymphoproliferative disorder.
Cancer. 2010 Jul 15;116(14):3521; author reply 3521-2. doi: 10.1002/cncr.25340.
3
Post-Transplant Lymphoproliferative Disorders.移植后淋巴细胞增生性疾病
Semin Nephrol. 2024 Jan;44(1):151503. doi: 10.1016/j.semnephrol.2024.151503. Epub 2024 Mar 22.
4
Post-transplant lymphoproliferative disorders.
S Afr J Surg. 1998 Feb;36(1):4, 6, 8-9.
5
The question of FK 506 nephrotoxicity after liver transplantation.
Transplant Proc. 1991 Feb;23(1 Pt 2):1444-7.
6
Infectious complications of immunosuppressive medications in organ transplant recipients.
Pediatr Infect Dis J. 2007 May;26(5):443-4. doi: 10.1097/01.inf.0000261010.28610.88.
7
Use of FK 506 in pediatric patients.
Transplant Proc. 1991 Feb;23(1 Pt 2):924-7.
8
The surgical implications of the posttransplant lymphoproliferative disorders.移植后淋巴增殖性疾病的外科手术意义
Transplant Proc. 1991 Feb;23(1 Pt 2):1477-9.
9
Lymphoproliferative disorder involving the cervix in a patient being treated with FK-506.
Gynecol Oncol. 1996 Aug;62(2):301-3. doi: 10.1006/gyno.1996.0231.
10
Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry.减少免疫抑制联合全脑放疗和同期全身利妥昔单抗治疗原发性中枢神经系统移植后淋巴组织增生性疾病（pCNS-PTLD）：来自前瞻性德国 PTLD 登记处的 14 例病例。
Ann Hematol. 2021 Aug;100(8):2043-2050. doi: 10.1007/s00277-021-04548-2. Epub 2021 May 11.
引用本文的文献
1
Post-transplant lymphoproliferative disorders.移植后淋巴组织增生性疾病。
Pathol Oncol Res. 1997 Sep;3(3):177-82. doi: 10.1007/BF02899918.
2
Long-term results of pediatric liver transplantation in a combined pediatric and adult transplant program.儿童与成人联合移植项目中儿童肝移植的长期结果
CMAJ. 2002 Jun 25;166(13):1663-71.
3
The role of EBV in post-transplant malignancies: a review.EBV在移植后恶性肿瘤中的作用：综述
J Clin Pathol. 2000 Apr;53(4):248-54. doi: 10.1136/jcp.53.4.248.
4
The antiviral prophylaxis of post-transplant lymphoproliferative disorder.移植后淋巴增生性疾病的抗病毒预防
Springer Semin Immunopathol. 1998;20(3-4):437-53. doi: 10.1007/BF00838054.
5
Clinical and pathological features of post-transplant lymphoproliferative disorders (PTLD).移植后淋巴细胞增生性疾病（PTLD）的临床和病理特征。
Springer Semin Immunopathol. 1998;20(3-4):325-42. doi: 10.1007/BF00838047.
6
Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation.他克莫司。其药理学及在肝移植和肾移植中的治疗潜力综述。
Drugs. 1993 Oct;46(4):746-94. doi: 10.2165/00003495-199346040-00009.
7
Posttransplant lymphoproliferative disorders occurring under primary FK 506 immunosuppression.在原发性FK 506免疫抑制下发生的移植后淋巴细胞增生性疾病。
Transplant Proc. 1991 Dec;23(6):3044-6.
8
Lymphoproliferative disease in organ transplant recipients.器官移植受者的淋巴增殖性疾病
Springer Semin Immunopathol. 1991;13(2):199-216. doi: 10.1007/BF00201469.
本文引用的文献
1
Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients.肾移植受者中的多形性弥漫性B细胞增生和淋巴瘤。
Cancer Res. 1981 Nov;41(11 Pt 1):4262-79.
2
Cancers following cyclosporine therapy.
Transplantation. 1987 Jan;43(1):32-5. doi: 10.1097/00007890-198701000-00008.
3
4
FK 506 for liver, kidney, and pancreas transplantation.用于肝脏、肾脏和胰腺移植的FK 506。
Lancet. 1989 Oct 28;2(8670):1000-4. doi: 10.1016/s0140-6736(89)91014-3.
5
A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase.免疫抑制剂FK506的一种受体是一种顺反肽基脯氨酰异构酶。
Nature. 1989 Oct 26;341(6244):758-60. doi: 10.1038/341758a0.
6
A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin.免疫抑制剂FK506的一种胞质结合蛋白具有肽基脯氨酰异构酶活性，但与亲环蛋白不同。
Nature. 1989 Oct 26;341(6244):755-7. doi: 10.1038/341755a0.
7
Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers.环孢素A最初作为唯一的免疫抑制剂应用于34例尸体器官接受者：32例肾移植、2例胰腺移植和2例肝移植。
Lancet. 1979 Nov 17;2(8151):1033-6. doi: 10.1016/s0140-6736(79)92440-1.
Zotero 插件